Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80⁺ PDL1^-)-pDC subset negatively correlated with clinical outcomes in melanoma patients.

ABSTRACT:

Objectives

Plasmacytoid DCs (pDCs) play a critical yet enigmatic role in antitumor immunity through their pleiotropic immunomodulatory functions. Despite proof of pDC diversity in several physiological or pathological contexts, pDCs have been studied as a whole population so far in cancer. The assessment of individual pDC subsets is needed to fully grasp their involvement in cancer immunity, especially in melanoma where pDC subsets are largely unknown and remain to be uncovered.

Methods

We explored for the first time the features of diverse circulating and tumor-infiltrating pDC subsets in melanoma patients using multi-parametric flow cytometry, and assessed their clinical relevance. Based on CD80, PDL1, CD2, LAG3 and Axl markers, we provided an integrated overview of the fr

SUBMITTER: Sosa Cuevas E 

PROVIDER: S-EPMC9063720 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature